Pancreatic Cancer Research

ResearcherVita-Salute San Raffaele UniversityActive in the last 2 years

Claudio Doglioni

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4969-5216; OpenAlex author ID A5047380313. Sources: OpenAlex.

Their work

Papers
43 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
0
Collaborators
121
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: 6 papers · 2017: 3 papers · 2018: 5 papers · 2019: 3 papers · 2020: 2 papers · 2021: 3 papers · 2022: 4 papers · 2023: 8 papers · 2024: 4 papers · 2025: 2 papers · 2026: 1 paper

Papers 43

  1. The H63D Polymorphism in the HFE Gene Promotes Aggressive Disease Phenotypes in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-25-4154↗
  2. Minimally Invasive vs Open Left Pancreatectomy for Resectable Pancreatic Cancer: Long-Term Results of the Randomized DIPLOMA Trial. Co-author DOI 10.1001/jamasurg.2025.4054↗
  3. Prognostic Validation of Perineural Invasion Severity Score in Pancreatic Cancer: A Prospective Study. Co-author DOI 10.1097/sla.0000000000006920↗
  4. Pathologic complete response following neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma: Impact on survival and recurrence. Co-author DOI 10.1016/j.surg.2024.07.026↗
  5. An alternative splicing signature defines the basal-like phenotype and predicts worse clinical outcome in pancreatic cancer. Co-author DOI 10.1016/j.xcrm.2024.101411↗
  6. Establishment of a Transplantation Model of PDAC-Derived Liver Metastases. Co-author DOI 10.1245/s10434-024-15514-3↗
  7. ASO Author Reflections: Bridging the Gap in PDAC Research: The Intraportal Model as a Platform for Studying Preclinical Liver Metastasis. Co-author DOI 10.1245/s10434-024-15655-5↗
  8. Ex-vivo investigation of radiofrequency ablation in pancreatic adenocarcinoma after neoadjuvant chemotherapy. Co-author DOI 10.1002/deo2.152↗
  9. Quantification of perineural invasion in pancreatic ductal adenocarcinoma: proposal of a severity score system. Last author DOI 10.1007/s00428-023-03574-x↗
  10. Routine Molecular Profiling in Both Resectable and Unresectable Pancreatic Adenocarcinoma: Relevance of Cytologic Samples. Co-author DOI 10.1016/j.cgh.2022.10.014↗
  11. Pro-tumor Tfh2 cells induce detrimental IgG4 production and PGE2-dependent IgE inhibition in pancreatic cancer. Co-author DOI 10.1016/j.ebiom.2023.104819↗
  12. Minimally invasive versus open distal pancreatectomy for resectable pancreatic cancer (DIPLOMA): an international randomised non-inferiority trial. Co-author DOI 10.1016/j.lanepe.2023.100673↗
  13. IL-1β+ macrophages fuel pathogenic inflammation in pancreatic cancer. Co-author DOI 10.1038/s41586-023-06685-2↗
  14. Pathological staging in postneoadjuvant pancreatectomy for pancreatic cancer: implications for adjuvant therapy. Co-author DOI 10.1093/bjs/znad146↗
  15. CA19.9 Response and Tumor Size Predict Recurrence Following Post-neoadjuvant Pancreatectomy in Initially Resectable and Borderline Resectable Pancreatic Ductal… Co-author DOI 10.1245/s10434-022-12622-w↗
  16. Histopathological tumour response scoring in resected pancreatic cancer following neoadjuvant therapy: international interobserver study (ISGPP-1). Co-author DOI 10.1093/bjs/znac350↗
  17. Proposal for a New Pathologic Prognostic Index After Neoadjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma (PINC). Last author DOI 10.1245/s10434-022-11413-7↗
  18. Needle-Tract Seeding of Pancreatic Cancer after EUS-FNA: A Systematic Review of Case Reports and Discussion of Management. Co-author DOI 10.3390/cancers14246130↗
  19. Differential EUS findings in focal type 1 autoimmune pancreatitis and pancreatic cancer: A proof-of-concept study. Co-author DOI 10.4103/eus-d-21-00111↗
  20. Exploring chemotherapy holiday and drugs re-challenge in advanced pancreatic cancer patients. Co-author DOI 10.1007/s00280-020-04190-1↗
  21. Amsterdam International Consensus Meeting: tumor response scoring in the pathology assessment of resected pancreatic cancer after neoadjuvant therapy. Co-author DOI 10.1038/s41379-020-00683-9↗
  22. Efficacy of Endoscopic Ultrasound-Guided Ablation with the HybridTherm Probe in Locally Advanced or Borderline Resectable Pancreatic Cancer: A Phase II Randomi… Co-author DOI 10.3390/cancers13184512↗
  23. Positive neck margin at frozen section analysis is a significant predictor of tumour recurrence and poor survival after pancreatodudenectomy for pancreatic can… Co-author DOI 10.1016/j.ejso.2020.02.013↗
  24. RNA Extraction from Endoscopic Ultrasound-Acquired Tissue of Pancreatic Cancer Is Feasible and Allows Investigation of Molecular Features. Co-author DOI 10.3390/cells9122561↗
  25. The IL-1/IL-1 receptor axis and tumor cell released inflammasome adaptor ASC are key regulators of TSLP secretion by cancer associated fibroblasts in pancreati… Co-author DOI 10.1186/s40425-019-0521-4↗
  26. Nerves and Pancreatic Cancer: New Insights into a Dangerous Relationship. Co-author DOI 10.3390/cancers11070893↗
  27. New era for pancreatic endoscopic ultrasound: From imaging to molecular pathology of pancreatic cancer. Co-author DOI 10.4251/wjgo.v11.i11.933↗
  28. A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreati… Co-author DOI 10.1016/j.ejca.2018.07.007↗
  29. Gene expression analysis of embryonic pancreas development master regulators and terminal cell fate markers in resected pancreatic cancer: A correlation with c… Co-author DOI 10.1016/j.pan.2018.09.006↗
  30. Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2-3 trial. Co-author DOI 10.1016/s2468-1253(18)30081-5↗
  31. Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial. Co-author DOI 10.1016/s2468-1253(18)30196-1↗
  32. Four-class tumor staging for early diagnosis and monitoring of murine pancreatic cancer using magnetic resonance and ultrasound. Co-author DOI 10.1093/carcin/bgy094↗
  33. A preoperative score to predict early death after pancreatic cancer resection. Co-author DOI 10.1016/j.dld.2017.06.012↗
  34. Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma. Co-author DOI 10.1093/annonc/mdx495↗
  35. Modeling the Iatrogenic Pancreatic Cancer Risk After Islet Autotransplantation in Mouse. Co-author DOI 10.1111/ajt.14360↗
  36. Phase II trial of salvage therapy with trabectedin in metastatic pancreatic adenocarcinoma. Co-author DOI 10.1007/s00280-015-2932-3↗
  37. Diabetes associated with pancreatic ductal adenocarcinoma is just diabetes: Results of a prospective observational study in surgical patients. Co-author DOI 10.1016/j.pan.2016.08.005↗
  38. Phase 1B trial of Nab-paclitaxel plus gemcitabine, capecitabine, and cisplatin (PAXG regimen) in patients with unresectable or borderline resectable pancreatic… Co-author DOI 10.1038/bjc.2016.209↗
  39. Basophil Recruitment into Tumor-Draining Lymph Nodes Correlates with Th2 Inflammation and Reduced Survival in Pancreatic Cancer Patients. Co-author DOI 10.1158/0008-5472.can-15-1801-t↗
  40. (Ir)relevance of Metformin Treatment in Patients with Metastatic Pancreatic Cancer: An Open-Label, Randomized Phase II Trial. Co-author DOI 10.1158/1078-0432.ccr-15-1722↗
  41. Effect of Diabetes on Survival after Resection of Pancreatic Adenocarcinoma. A Prospective, Observational Study. Co-author DOI 10.1371/journal.pone.0166008↗
  42. A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirub… Co-author DOI 10.1007/s00280-011-1680-2↗
  43. Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancrea… Co-author DOI 10.1084/jem.20101876↗

Closest collaborators

The 25 strongest of 121 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Massimo Falconi · 31 shared papers, 2016–2026 · strength 3.51
  2. Michele Reni · 24 shared papers, 2011–2025 · strength 2.14
  3. Marco Schiavo Lena · 12 shared papers, 2019–2025 · strength 1.88
  4. Gianpaolo Balzano · 20 shared papers, 2012–2023 · strength 1.62
  5. Stefano Crippa · 12 shared papers, 2017–2025 · strength 1.60
  6. Giulio Belfiori · 11 shared papers, 2017–2025 · strength 1.54
  7. Paolo Giorgio Arcidiacono · 13 shared papers, 2016–2024 · strength 1.46
  8. Erica Dugnani · 11 shared papers, 2016–2024 · strength 0.97
  9. Lorenzo Piemonti · 11 shared papers, 2016–2024 · strength 0.97
  10. Gabriele Capurso · 7 shared papers, 2019–2024 · strength 0.93
  11. Maria Chiara Petrone · 7 shared papers, 2019–2023 · strength 0.91
  12. Giulia Gasparini · 6 shared papers, 2019–2025 · strength 0.89
  13. Maria Giulia Cangi · 5 shared papers, 2016–2025 · strength 0.72
  14. Lívia Archibugi · 5 shared papers, 2019–2024 · strength 0.66
  15. Miriam Redegalli · 5 shared papers, 2019–2023 · strength 0.65
  16. Gemma Rossi · 5 shared papers, 2020–2023 · strength 0.60
  17. Marina Macchini · 5 shared papers, 2018–2024 · strength 0.58
  18. Stefano Partelli · 4 shared papers, 2018–2025 · strength 0.57
  19. Sabrina Gloria Giulia Testoni · 5 shared papers, 2019–2023 · strength 0.56
  20. Domenico Tamburrino · 3 shared papers, 2021–2025 · strength 0.52
  21. Claudio Luchini · 4 shared papers, 2021–2023 · strength 0.49
  22. Giulia Orsi · 3 shared papers, 2021–2024 · strength 0.45
  23. Silvia Matilde Zanon · 6 shared papers, 2016–2021 · strength 0.42
  24. Valentina Pasquale · 7 shared papers, 2016–2018 · strength 0.41
  25. Paolo Riccardo Camisa · 2 shared papers, 2024 · strength 0.40

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.